CRIS Current Research Information System

PALLONI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.280
EU - Europa 1.811
AS - Asia 852
AF - Africa 122
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 5.078
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.262
IT - Italia 498
SE - Svezia 326
GB - Regno Unito 301
SG - Singapore 257
CN - Cina 236
DE - Germania 199
VN - Vietnam 180
IE - Irlanda 116
CH - Svizzera 113
IN - India 93
FI - Finlandia 52
FR - Francia 40
TG - Togo 40
RU - Federazione Russa 39
CI - Costa d'Avorio 32
JO - Giordania 26
NG - Nigeria 24
ZA - Sudafrica 22
BG - Bulgaria 20
EE - Estonia 18
GR - Grecia 18
ID - Indonesia 16
UA - Ucraina 14
CA - Canada 13
NL - Olanda 13
TR - Turchia 11
BE - Belgio 9
PS - Palestinian Territory 9
KR - Corea 8
PL - Polonia 7
AT - Austria 6
CL - Cile 4
NI - Nicaragua 4
BR - Brasile 3
ES - Italia 3
IR - Iran 3
PT - Portogallo 3
RO - Romania 3
SC - Seychelles 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
CZ - Repubblica Ceca 2
HU - Ungheria 2
JP - Giappone 2
LT - Lituania 2
RS - Serbia 2
SI - Slovenia 2
AR - Argentina 1
BD - Bangladesh 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
IQ - Iraq 1
LB - Libano 1
MD - Moldavia 1
MX - Messico 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
VE - Venezuela 1
Totale 5.078
Salva come PNG Salva come JPEG
Città #
Chandler 318
Southend 267
Singapore 235
Fairfield 224
Ashburn 165
Dong Ket 126
Houston 122
Dublin 116
Santa Clara 108
Bern 107
Princeton 100
Bologna 95
Wilmington 90
Woodbridge 86
Seattle 85
Cambridge 64
Boardman 63
Ann Arbor 57
Helsinki 47
Lomé 40
New York 40
Rome 33
Abidjan 32
Berlin 32
Redmond 32
Nanjing 28
Turin 28
Beijing 27
Amman 26
Milan 25
Westminster 25
Abeokuta 24
Frankfurt am Main 22
Sofia 20
Florence 16
Jakarta 16
San Diego 16
Padova 14
Jinan 13
Medford 13
Ravenna 11
Des Moines 10
Olalla 10
Halhul 9
Hyderabad 9
Los Angeles 9
Shanghai 9
Brussels 8
Shenyang 8
Toronto 8
Istanbul 7
London 7
Torino 7
Zhengzhou 7
Bremen 6
Bühl 6
Hangzhou 6
Hebei 6
Nanchang 6
Saint Petersburg 6
Washington 6
Dearborn 5
Fremont 5
Guangzhou 5
Haikou 5
Hefei 5
Lappeenranta 5
Redwood City 5
Tianjin 5
Vienna 5
Amsterdam 4
Athens 4
Fontanelice 4
Jiaxing 4
Managua 4
Mountain View 4
Napoli 4
Norwalk 4
Paris 4
Parma 4
Pune 4
Tulsa 4
Wuhan 4
Wuxi 4
Austin 3
Boydton 3
Changsha 3
Council Bluffs 3
Kunming 3
Leawood 3
Mahé 3
Moscow 3
Ningbo 3
Ottawa 3
Phoenix 3
Plauen 3
San Mateo 3
São Paulo 3
Trieste 3
Warsaw 3
Totale 3.307
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 276
Adjuvant treatment in biliary tract cancer 211
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 171
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 171
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 162
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 160
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 154
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 149
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 146
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 144
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 135
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 133
Bone metastases in biliary cancers: A multicenter retrospective survey 132
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 124
In Reply 123
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 118
State of the art biological therapies in pancreatic cancer 115
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 115
Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 112
Discovery of new potential actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 111
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 111
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 109
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 109
Chemotherapy in Patients with Advanced Cholangiocarcinoma 107
Radiotherapy or chemoradiation in unresectable biliary cancer: A retrospective study 103
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 100
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 99
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 83
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 78
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 78
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 76
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 75
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 71
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 69
Experimental HER2- targeted therapies for biliary tract cancer 69
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 68
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 67
Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma? 63
Hacking pancreatic cancer: Present and future of personalized medicine 63
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 61
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 59
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 58
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 54
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 49
The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center 48
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 48
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 46
Nivolumab: an investigational agent for the treatment of biliary tract cancer 44
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 43
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 41
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 38
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 35
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 30
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 25
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 25
The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center 23
Prognostic value of integrated morphofunctional imaging methods in inoperable intrahepatic cholangiocarcinoma 17
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma 9
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 5
Totale 5.318
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.771
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.771
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020491 0 0 0 0 0 74 92 93 109 58 39 26
2020/2021605 81 20 13 7 5 28 61 45 62 34 37 212
2021/20221.067 68 37 43 75 70 34 26 73 135 113 236 157
2022/20231.407 125 203 71 141 101 101 45 83 224 64 92 157
2023/2024471 76 55 32 42 37 81 20 27 15 37 28 21
2024/2025813 100 200 163 119 169 62 0 0 0 0 0 0
Totale 5.318